Intersect ENT (XENT) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
Intersect ENT Reports Third Quarter 2020 Financial Results
November 2, 2020 7:00 AM ESTMENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today reported financial results for the third quarter ended September 30, 2020.
Third Quarter 2020 Overview
Revenue of $22.7 million in the third quarter of 2020, compared to $24.1 million in the third quarter of 2019Strong sales trend reinforces confidence in fourth quarter 2020 sequential revenue growth
Cash, Cash Equivalents and Short-term Investments of $130.7 million
Total revenue was $22.7 million for the third quarter of 2020, compared to... More
